Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 17/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 16/20 | 0.34 |
| ▸ | PDE4A | P27815 | 13/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | AKT2 | P31751 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1746576 | 0.83 | MKNK1 (0.49) | MKNK1RIPK3PDE4BPDE4DPDE4A | |
| SCHEMBL22189751 | 0.81 | AKT1 (0.48) | RIPK3PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL456971 | 0.71 | MKNK1 (0.37) | MKNK1RIPK3PDE4BPDE4DPDE4A | |
| SCHEMBL22189658 | 0.71 | PDE4D (0.61) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL22322759 | 0.70 | MKNK1 (0.41) | MKNK1 | |
| SCHEMBL3357770 | 0.70 | MKNK1 (0.71) | MKNK1 | |
| SCHEMBL1745964 | 0.68 | PDE4A (0.48) | MKNK1PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL4710579 | 0.64 | MKNK1 (0.49) | MKNK1RIPK3PDE4BPDE4DPDE4A | |
| SCHEMBL2068562 | 0.62 | PDE4B (0.35) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL2066630 | 0.62 | CA1 (0.36) | MKNK1PDE4BPDE4DPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9108971-B2 | 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]-pyridazine and derivatives thereof preparation and therapeutic application thereof | SANOFI (FR) | 2015-08-18 | — | — | US | disclosed |
| US-20130245023-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI (FR) | 2013-09-19 | — | — | US | disclosed |
| EP-2178879-B1 | 6-CYCLOAMINO-S-(PYRIDAZIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2013-07-03 | — | — | EP | disclosed |
| US-8455491-B2 | 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]pyridazine and derivatives and pharmaceutical compositions comprising the same | SANOFI (FR) | 2013-06-04 | — | — | US | disclosed |
| US-20100152157-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245023-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | TLR7, IFNAR1, CBR3 | MKNK1 4608/4885RIPK3 3773/4885PDE4B 473/4885 |
| US-20100152157-A1 | 6-CYCLOAMINO-3-(PYRIDAZIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND DERIVATIVES THEREOF PREPARATION AND THERAPEUTIC APPLICATION THEREOF | IFNAR1, TLR7, CBR3 | MKNK1 4579/4885RIPK3 3634/4885PDE4B 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.